APPLICATION
ANDA206863
TYPE
ANDA
ORIGINAL APPROVAL
2018-07-11
LATEST ACTION
2026-04-20
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
DALFAMPRIDINEPrescription
DALFAMPRIDINE 10MG · TABLET, EXTENDED RELEASE · ORAL
Approval history
2026-04-20Labeling · Supplement 4 · standardAP
2023-05-01Labeling · Supplement 3 · standardAP
2018-07-11UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.